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IMPORTANCE In clinical guidelines, overt and subclinical thyroid dysfunction are mentioned as
causal and treatable factors for cognitive decline. However, the scientific literature on these
associations shows inconsistent findings.
OBJECTIVE To assess cross-sectional and longitudinal associations of baseline thyroid
dysfunction with cognitive function and dementia.
DESIGN, SETTING, AND PARTICIPANTS This multicohort individual participant data analysis
assessed 114 267 person-years (median, 1.7-11.3 years) of follow-up for cognitive function and
525 222 person-years (median, 3.8-15.3 years) for dementia between 1989 and 2017.
Analyses on cognitive function included 21 cohorts comprising 38 144 participants. Analyses
on dementia included eight cohorts with a total of 2033 cases with dementia and 44 573
controls. Data analysis was performed from December 2016 to January 2021.
EXPOSURES Thyroid function was classified as overt hyperthyroidism, subclinical
hyperthyroidism, euthyroidism, subclinical hypothyroidism, and overt hypothyroidism based
on uniform thyrotropin cutoff values and study-specific free thyroxine values.
MAIN OUTCOMES AND MEASURES The primary outcome was global cognitive function, mostly
measured using the Mini-Mental State Examination. Executive function, memory, and
dementia were secondary outcomes. Analyses were first performed at study level using
multivariable linear regression and multivariable Cox regression, respectively. The studies
were combined with restricted maximum likelihood meta-analysis. To overcome the use of
different scales, results were transformed to standardized mean differences. For incident
dementia, hazard ratios were calculated.
RESULTS Among 74 565 total participants, 66 567 (89.3%) participants had normal thyroid
function, 577 (0.8%) had overt hyperthyroidism, 2557 (3.4%) had subclinical
hyperthyroidism, 4167 (5.6%) had subclinical hypothyroidism, and 697 (0.9%) had overt
hypothyroidism. The study-specific median age at baseline varied from 57 to 93 years; 42 847
(57.5%) participants were women. Thyroid dysfunction was not associated with global
cognitive function; the largest differences were observed between overt hypothyroidism and
euthyroidism—cross-sectionally (−0.06 standardized mean difference in score; 95% CI, –0.20
to 0.08; P = .40) and longitudinally (0.11 standardized mean difference higher decline per
year; 95% CI, –0.01 to 0.23; P = .09). No consistent associations were observed between
thyroid dysfunction and executive function, memory, or risk of dementia.
CONCLUSIONS AND RELEVANCE In this individual participant data analysis of more than
74 000 adults, subclinical hypothyroidism and hyperthyroidism were not associated with
cognitive function, cognitive decline, or incident dementia. No rigorous conclusions can be
drawn regarding the role of overt thyroid dysfunction in risk of dementia. These findings do
not support the practice of screening for subclinical thyroid dysfunction in the context of
cognitive decline in older adults as recommended in current guidelines.
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T hyroid dysfunction is considered a potentially revers-ible cause of cognitive decline; hence, thyroid func-tion screening tests are described in guidelines as an es-
sential component of the workup for the diagnosis of
dementia.1-3 Thyroid dysfunction is frequently observed in in-
dividuals with suspected dementia.4 However, the outcomes
of treatment of overt hypothyroidism and hyperthyroidism and
subclinical hyperthyroidism on cognitive function are not fully
clarified.5-7 For subclinical hypothyroidism, 4 of 5 recent ran-
domized clinical trials and a meta-analysis on levothyroxine
treatment did not find evidence for an improvement in cog-
nitive function.8-13 Moreover, meta-analyses of observa-
tional studies have yielded inconsistent results on associa-
tions of subclinical and overt thyroid dysfunction with
cognitive impairment and risk of dementia.14-17 An individual
participant data analysis of cohort studies might help clarify
the conflicting results of previous studies, as it allows for uni-
form definitions of thyroid dysfunction and it can assess the
differential associations by age groups, sex, and thyroid medi-
cation in subgroup analyses.18 In the present study, we inves-
tigated cross-sectional and longitudinal associations of thy-
roid dysfunction with cognitive function and dementia in an
individual participant data analysis of multiple cohorts.
Methods
Study Population
We first approached the coordinating center of the Thyroid
Studies Collaboration, a collaborative project of 25 existing lon-
gitudinal studies with information on thyroid status.18 The
Medical Ethics Committee of the Leiden University Medical
Center waived the need for review owing to the retrospective
nature of the study using only previously collected data; no
individuals underwent interventions for the present study.
Each participant gave informed consent to the original study
they participated in, which was oral or written depending on
the original study design and legislation at the time of data col-
lection. All 15 Thyroid Studies Collaboration cohorts that had
collected data on cognitive function or dementia joined the
project. The study designs for all cohorts participating in the
current study have been described previously in more
detail.19-33 We approached 14 additional cohorts that were ex-
tracted from 4 recent meta-analyses on subclinical thyroid dys-
function and cognitive function or dementia.14-17 Six of these
cohorts consented to collaborating and sharing data.34-39 Lastly,
we included publicly available data of the National Health and
Nutrition Examination Survey waves of 1999 to 2002 and 2011
to 2012, which simultaneously collected thyroid and cogni-
tive function among many other parameters.40
Thyroid Function
Thyroid dysfunction was determined biochemically by mea-
surements of thyrotropin and free thyroxine (FT4) concentra-
tions in all cohorts. Cohort-specific cutoff values were used for
FT4 levels (eTable 1 in the Supplement). In accordance with pre-
vious projects in the Thyroid Studies Collaboration, partici-
pants were classified as euthyroid if thyrotropin level was 0.45
to 4.49 mIU/L.18 Overt hyperthyroidism was defined as a thy-
rotropin level less than 0.45 mIU/L and FT4 level above the ref-
erence range. Subclinical hyperthyroidism was defined as a thy-
rotropin level less than 0.45 mIU/L and FT4 levels within the
reference range, or only as thyrotropin level less than
0.45 mIU/L in absence of an FT4 measurement (n = 896 among
10 cohorts) because overt hyperthyroidism is rare.41 A combi-
nation of thyrotropin level of 4.50 to 20 mIU/L and FT4 levels
within the reference range was defined as subclinical hypo-
thyroidism. Individuals who had missing FT4 measurements
with mildly elevated thyrotropin levels (4.50-20 mIU/L) were
considered subclinically hypothyroid (n = 523 among 8 co-
horts) because chances of overt hypothyroidism in this pa-
tient category are low.41 A thyrotropin level of 20 mIU/L or
greater or thyrotropin level of 4.50 mIU/L or greater com-
bined with FT4 levels below the reference range was defined
as overt hypothyroidism.
Cognitive Function
The primary outcome was global cognitive function mea-
sured by Mini-Mental State Examination (MMSE), Modified
Mini-Mental State (3MS), or Severe Cognitive Impairment Rat-
ing Scale.42-44 A difference of 1 point in MMSE score is consid-
ered the minimal clinically important difference in individu-
als without dementia.45 Executive function and memory were
secondary outcomes. For executive function, various tests were
used: Digit Symbol Substitution Test, Trail Making Test B, Let-
ter Digit Substitution Test (LDST), Executive Interview 15, and
Ruff Figural Fluency Test.46-50 The minimal clinically impor-
tant difference for executive function was defined as a differ-
ence of 4 points in LDST.51 Memory was measured using either
Rey’s Auditory Verbal Learning Test (also referred to as Word
Learning Test or Verbal Learning Test), Digit Span Test, or Vi-
sual Association Test.52-55 No minimal clinically important dif-
ference for memory tests was found in the literature.
Dementia
Depending on the study design, dementia was diagnosed either
in a clinical setting or at a research center. The diagnosis was,
at least in part, based on clinical presentation. Studies in which
dementia diagnosis was based only on a cutoff point for the
Key Points
Question Is thyroid dysfunction associated with cognitive
decline?
Findings In this individual participant data analysis of 23 cohorts
including 74 565 participants with cognitive function and/or
dementia measurements, subclinical thyroid dysfunction was not
associated with global cognitive function at baseline (standardized
mean difference, −0.02 for subclinical hyperthyroidism and 0.05
for subclinical hypothyroidism) or annual decline (standardized
mean difference, −0.02 for subclinical hyperthyroidism and −0.00
for subclinical hypothyroidism).
Meaning These findings do not support the need for screening for
subclinical thyroid dysfunction for prevention of cognitive decline
or dementia.
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MMSE were excluded from this analysis because cognitive
function tests are insufficient to diagnose dementia.56 Preva-
lence of dementia at baseline was available for 11 cohorts; 431
participants had a diagnosis of dementia at baseline, but only
78 of them were classified as noneuthyroid. Owing to the small
number of participants with thyroid dysfunction at baseline,
no cross-sectional analyses for dementia were performed.
Statistical Analyses
We used a 2-stage individual participant data analysis ap-
proach, which accommodates uniform definitions and analy-
ses for each cohort while keeping complexity to a
minimum.18,57 The first stage consisted of study-level analy-
sis of thyroid dysfunction and cognitive function or demen-
tia conducted on the original data sets with participant-level
data. In the second stage, the effect estimates from the first
stage were pooled using a random-effects model based on re-
stricted maximum likelihood. Heterogeneity across studies was
quantified using the I2 statistic: less than 40% was consid-
ered low heterogeneity; 40% to 75%, moderate heteroge-
neity; and greater than 75%, high heterogeneity.
For both the cross-sectional and longitudinal analyses be-
tween thyroid dysfunction and cognitive function, we used
multivariable linear regression models. To facilitate combina-
tion of different scales, the results were transformed to stan-
dardized mean differences. In the prospective analysis of cog-
nitive decline, we calculated the difference between the last
available measurement of cognitive function and baseline cog-
nitive function. The difference was divided by the follow-up
time in years to obtain an annual decline, irrespective of du-
ration of follow-up. The annual decline was subsequently stan-
dardized, resulting in a standardized mean difference in an-
nual change in cognitive function allowing comparison of
changes over time.
The risk of developing dementia during follow-up was as-
sessed using Cox regression models. In these analyses, par-
ticipants with dementia at baseline were excluded. For stud-
ies without precise registration of the date of dementia
diagnosis, it was assumed that dementia developed halfway
between the registration date and the last date that absence
of dementia was ascertained.
Thyroid dysfunction (overt hyperthyroidism, subclinical
hyperthyroidism, subclinical hypothyroidism, and overt hy-
pothyroidism) was included as a categorical variable with the
euthyroid group serving as reference. All analyses were ad-
justed for age and sex. The longitudinal analyses of cognitive
decline were adjusted for baseline cognitive function. Pre-
specified subgroup analyses were performed by stratifica-
tion and interaction analysis for sex and for age younger or older
than 75 years. Additional analyses were performed with ad-
justment for educational attainment, though this variable was
not available in all cohorts. In sensitivity analyses, partici-
pants with missing FT4 measurements in the subclinical hy-
perthyroid and subclinical hypothyroid groups were ex-
cluded, as were those who used antithyroid medication or
thyroid hormone replacement therapy at baseline. Further-
more, we assessed robustness of the associations by pooling
the estimates using fixed-effect models and by excluding stud-
ies with strata of fewer than 10 participants. To assess whether
effects were dependent on degree of disruption of thyrotro-
pin, analyses were repeated with thyrotropin categories of less
than 0.10 mIU/L, 0.10 to 0.44 mIU/L, 4.5 to 6.9 mIU/L, 7.0 to
10 mIU/L, and greater than 10 mIU/L, in which participants with
thyrotropin between 0.45 and 4.49 mIU/L served as refer-
ence. Lastly, instead of using biochemical cutoff points, thy-
rotropin and FT4 were analyzed continuously across the full
range with cognitive function. Thyrotropin was transformed
using the natural logarithm; for both natural log-transformed
thyrotropin and FT4, models were constructed per standard
deviation. Continuous models were performed minimally ad-
justed by age and sex and with additional adjustment for edu-
cational attainment. For sensitivity purposes, the analyses were
also conducted excluding the participants who used antithy-
roid medication or thyroid hormone replacement therapy at
baseline. Cohorts with greater than 10% missing measure-
ments for FT4 were excluded for the continuous analyses on
FT4. All P values were 2-tailed; statistical significance was set
at P < .05.
Study-level analyses were performed using SPSS Statis-
tics, version 25 (IBM). Effect estimates were pooled and sum-
marized in forest plots using R, version 3.6.1 and metafor pack-
age (R Foundation for Statistical Computing).58 This study
followed the Strengthening the Reporting of Observational
Studies in Epidemiology (STROBE) reporting guideline.
Results
Population Characteristics
Individual participant data on thyroid function and cognitive
function and/or dementia were provided by 23 cohorts com-
prising 74 565 participants. At baseline, 66 567 (89.3%) par-
ticipants were biochemically classified as euthyroid, 577 (0.8%)
as overtly hyperthyroid, 2557 (3.4%) as subclinically hyper-
thyroid, 4167 (5.6%) as subclinically hypothyroid, and 697
(0.9%) as overtly hypothyroid (eTable 1 in the Supplement).
The study-specific median age at baseline varied from 57 to
93 years; 42 847 (57.5%) participants were women.
A total of 38 144 participants from 21 cohorts provided data
on a measure of cognitive function (Table). The median age var-
ied from 58 to 93 years, and 18 089 (47.4%) participants were
women. Follow-up for cognitive decline was available for 14
cohorts, with a median follow-up duration varying from 1.7 to
11.3 years, accumulating 114 267 person-years.
Eight cohorts provided follow-up for dementia incidence
on 46 606 participants (eTable 2 in the Supplement). Among
these participants, 28 820 (61.8%) were women, and the me-
dian age at baseline was between 57 and 85 years. During fol-
low-up, 2033 (4.4%) cases of incident dementia were identi-
fied. Median follow-up duration ranged from 3.8 to 15.3 years,
accumulating 525 222 person-years.
Thyroid Dysfunction and Global Cognitive Function
Cross-sectionally, thyroid dysfunction was not associated with
global cognitive function among 18 cohorts (Figure 1;
eFigure1intheSupplement).Thelargestobserveddifferencewas
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−0.06 standardized mean difference (95% CI, −0.20 to 0.08; P =
.40)globalcognitivefunctionforoverthypothyroidismcompared
with euthyroidism, which could be interpreted as an approxi-
mately 0.1-point lower MMSE score based on the SD for the 2 larg-
est cohorts included. No statistically significant association was
observed between thyroid dysfunction at baseline and annual
change in global cognitive function during follow-up among 13
cohorts (Figure 2). Participants with overt hypothyroidism had
0.11standardizedmeandifference(95%CI,−0.01to0.23;P = .09)
higher decline per year in global cognitive function than partici-
pants who were euthyroid, which translates to approximately 0.1
point on the MMSE scale faster decline per year based on the SD
in the largest cohort for this analysis. Additional adjustment for
educationalattainmentdidnotmateriallychangetheresults(eFig-
ure 2 in the Supplement). Stratification by age and sex did not
showanydifferentialeffectsforglobalcognitivefunction(eTable3
in the Supplement). No statistically significant associations were
found when individuals were categorized by severity of thyro-
tropin abnormality (eFigure 3 in the Supplement). Reanalyzing
the data with a fixed-effects model or without strata with fewer
than 10 participants did not yield different results (eTable 4 in the
Supplement).LeavingoutparticipantswithmissingFT4 measure-
ments or those using antithyroid medication or thyroid hormone
replacement therapy at baseline also did not change the results.
A positive association was found between continuous thyrotro-
pin and global cognition only when thyroid supplementation and
antithyroid medication users were excluded (0.028 higher stan-
dardized mean difference per SD; 95% CI, 0.003 to 0.053; P = .03;
eTable 5 in the Supplement). No association between continuous
FT4 levelsandglobalcognitivefunctionwasfound.Heterogeneity
across studies was low for the cross-sectional main analyses (I2 =
0%-40%), while heterogeneity was low to moderate for the lon-
gitudinal and sensitivity analyses (I2 = 0%-70%).
Thyroid Dysfunction and Executive Function and Memory
No negative association was observed cross-sectionally be-
tween thyroid dysfunction and executive function or memory
among 11 and 8 cohorts, respectively (Figure 1; eFigures 4 and
5 in the Supplement). Participants with overt hyperthyroid-
ism had 0.20 standardized mean difference (95% CI, 0.07 to
0.33; P = .002) higher executive function score compared with
participants who were euthyroid; transformed, this would ac-
count for 1.6 more correct substitutions within 60 seconds for
the LDST based on the largest cohort in this analysis. In both
executive function and memory, participants with subclini-
cal hypothyroidism performed better than participants who
were euthyroid (executive function: 0.07 standardized mean
difference; 95% CI, 0.01 to 0.13; P = .03; memory: 0.08 stan-
dardized mean difference; 95% CI, 0.01 to 0.15; P = .03). Lon-
gitudinally, no association was found between thyroid dys-
function at baseline and decline in executive function among
7 cohorts or memory among 6 cohorts; all differences were
smaller than 0.1 standardized mean difference (Figure 2). Ad-
ditional adjustment for educational attainment did not mate-
rially change the results (eFigure 2 in the Supplement). No sta-
tistically significant interaction with sex or age was present
(P > .05 for all; supporting data in eTable 3 in the Supple-
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fewer than 10 participants did not change the results for ex-
ecutive function or memory (eTable 4 in the Supplement). The
association of subclinical hypothyroidism and better execu-
tive function was attenuated when participants with missing
FT4 measurements were left out, while the association with
memory was unchanged. The positive association between
overt hyperthyroidism and executive function disappeared
when participants using thyroid medication were removed. No
association was found when individuals were categorized by
severity of thyrotropin abnormality or when thyrotropin level
was analyzed continuously (eFigure 3 and eTable 5 in the
Supplement). Continuous analysis of FT4 levels showed a posi-
tive association with executive function (0.019 higher stan-
dardized mean difference per SD; 95% CI, 0.002 to 0.036;
P = .03), which was attenuated when participants using thy-
roid medication were left out. Heterogeneity across studies was
low for the cross-sectional main analyses (I2 = 0%-40%), while
heterogeneity was low to moderate for the longitudinal analy-
ses (I2 = 0%-70%) and up to high heterogeneity in the sensi-
tivity analyses (I2 ≤ 73%).
Thyroid Dysfunction and Dementia
Cross-sectional analysis of thyroid dysfunction and demen-
tia were unfeasible owing to few participants who were not eu-
Figure 1. Cross-sectional Association Between Thyroid Dysfunction and Cognitive Function Test Scores
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Figure 2. Longitudinal Association Between Thyroid Dysfunction and Cognitive Function Test Scores
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thyroid with dementia at baseline (78 participants among 11
cohorts). In longitudinal analyses among 12 cohorts, no asso-
ciation was found between thyroid dysfunction and incident
dementia (Figure 3; eFigure 6 in the Supplement). The haz-
ard ratio of dementia ranged from 1.54 (95% CI, 0.76 to 3.10)
for overt hyperthyroidism to 0.79 (95% CI, 0.48 to 1.28) for
overt hypothyroidism. Continuous analysis of thyrotropin and
FT4 levels also did not provide evidence for an association; haz-
ard ratio, 0.96 per SD increase of natural log-transformed thy-
rotropin (95% CI, 0.91 to 1.02; P = .16); hazard ratio, 1.05 per
SD increase of FT4 (95% CI, 0.98 to 1.13; P = .16). Heteroge-
neity between studies was low (I2 = 0%-40%).
Discussion
In this individual participant data analysis of 74 565 partici-
pants from 23 cohorts, there was no association between sub-
clinical thyroid dysfunction and cognitive function, cogni-
tive decline, or the onset of dementia. Owing to uncertainty
of the results for overt hypothyroidism and hyperthyroidism,
no rigorous conclusions can be drawn regarding the associa-
tion between overt thyroid dysfunction and cognitive de-
cline and dementia.
While prior study-level meta-analyses also reported no as-
sociation between subclinical hypothyroidism and cognitive
function, cognitive decline, or dementia, they were limited by
heterogeneity in definitions of thyroid dysfunction and choices
of covariates in the statistical models.14-17 Because we per-
formed an individual participant data analysis, we could stan-
dardize definitions of thyroid function categories and of cog-
nitive function and cognitive decline and standardize the
statistical models. By addressing these limitations and reach-
ing the same results, the present study provides the strongest
observational evidence to date suggesting that subclinical hy-
pothyroidism is not associated with cognitive function or cog-
nitive decline.
Various studies and 2 meta-analyses did show an associa-
tion between subclinical or overt hyperthyroidism or low thy-
rotropin level within the reference range and a higher risk of
dementia.14,17,20,26,59-61 Although our findings for subclinical
and overt hyperthyroidism and dementia did not reach sta-
tistical significance, they are directionally consistent with the
literature. Despite combining 8 cohorts comprising more than
45 000 participants, the number of individuals with subclini-
cal and overt hyperthyroidism and the number of individuals
who developed dementia during follow-up are limited. There-
fore, we cannot exclude a higher risk of dementia in individu-
als with hyperthyroidism. In addition, individuals with overt
hyperthyroidism had a slightly higher rate of cognitive de-
cline, though not statistically significant. Considering the ex-
isting literature and the other results in the present study, the
observed cross-sectional association between overt hyperthy-
roidism and better executive function was most likely a chance
finding. Moreover, the observed difference in executive func-
tion was less than half the minimal clinically important dif-
ference, making it a clinically insignificant finding regardless
of the P value.
Higher vulnerability among subgroups has been pro-
posed; younger adults and women might be more suscep-
tible to cognitive dysregulation associated with thyroid
dysfunction.16,62 Moreover, cognitive decline might only
be present in individuals with more extreme values of
thyrotropin,21,63 or variation in FT4 instead of thyrotropin lev-
els could be associated with dementia risk.22 In the present
multicohort study, we did not observe differential associa-
tions for participants younger and older than 75 years or for
men and women, nor any association with variation in FT4 level
or more extreme values of thyrotropin. Therefore, subgroup
associations reported in prior studies might not be generaliz-
able outside the original cohorts.
As mentioned before, all but 1 randomized clinical trial on
levothyroxine treatment for subclinical hypothyroidism also
did not provide evidence for improvement of cognitive
function.8-12 Moreover, both undertreatment and overtreat-
ment with levothyroxine are common, estimated at 27% and
14%, respectively.64 Overtreatment is associated with in-
creased risk of atrial fibrillation and atherosclerosis65,66 and,
via cerebrovascular damage, might be associated with in-
creased risk of cognitive decline. Therefore, screening for sub-
clinical thyroid dysfunction in older adults to prevent cogni-
tive impairment and dementia does not appear to be effective.
The current individual participant data analysis has several
strengths.Theuseofindividualparticipantdatafromcohortsfrom
all over the globe enhances generalization while allowing stan-
dardized definitions and relevant subgroup analyses. All but 5 of
the included studies had a median age of 70 years or older, which
isessentialbutoftennotthecaseinresearchconcerningoutcomes
that are most relevant for older adults.67 The present study ap-
proached cognition comprehensively; we assessed multiple do-
mains of cognitive function, cross-sectionally and longitudinally,
and incidence of dementia.
Figure 3. Longitudinal Association Between Thyroid Dysfunction and Incident Dementia
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Hazard ratios were adjusted for age
and sex. Error bars indicate 95% CIs.
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Limitations
Some limitations need to be acknowledged. Thyroid function
categorization was based on biochemical characteristics. For
20% to 30% of the participants who were categorized as sub-
clinical hypothyroid or hyperthyroid, we could not confirm
subclinical thyroid dysfunction owing to the absence of FT4
measurement. This may have led to some misclassification, yet
sensitivity analyses excluding those participants with miss-
ing FT4 data yielded similar results. We could not include edu-
cational attainment in our main analysis because 5 out of 18
cohorts did not collect these data. Even though the sensitiv-
ity analyses with adjustment for educational attainment
yielded similar results as the main analysis, education is a pos-
sible confounder that could not be accounted for. For most co-
horts, only 1 measurement of thyroid function was available,
which is why only baseline thyroid function was used in the
present individual participant data analysis. This study could
therefore not capture any changes in cognitive function that
might occur at the transition of one thyroid status to another.
Moreover, for the vast majority of study participants, a maxi-
mum of 2 measurements of cognitive function was available,
which precluded advanced modeling of change over time in-
cluding nonlinear trajectories. In addition, the interpretation
of longitudinal studies of cognitive function can be compli-
cated by practice effects.68 Standardization of change over time
might not fully alleviate this; hence, residual practice effects
may still be present. Furthermore, because dementia is clini-
cally difficult to diagnose, some misclassification could have
occurred, which may have led to an underestimation of the as-
sociation. In addition, the number of incident dementia cases
in the included cohort studies was low; we therefore cannot
rule out a clinically relevant association between thyroid dys-
function and risk of dementia. The heterogeneity between
studies may have been increased by the use of different cog-
nitive function tests, different durations of follow-up, differ-
ences in age and sex distribution, different lifestyles across con-
tinents, and different inclusion criteria. As heterogeneity was
expected a priori, we performed all meta-analyses with ran-
dom effects. Nonetheless, results for fixed-effects meta-
analyses were not materially different. The observed hetero-
geneity was larger in the longitudinal analyses heterogeneity
(I2 = 0%-70%) than in the cross-sectional analyses (I2 = 0%-
40%), likely owing to the additional variation of follow-up du-
ration. We hypothesize that the minor differences in I2 esti-
mates between different cross-sectional analyses are
attributable to differences in sample size per exposure. Be-
cause individuals with thyroid disease generally receive medi-
cal treatment, we cannot address the question of whether long-
term untreated hyperthyroidism or hypothyroidism is
associated with cognitive function and dementia risk. More-
over, these results only apply to objectifiable cognitive de-
cline, which is not synonymous with the more subjective cog-
nitive complaints.
Conclusions
In this individual participant data analysis combining the in-
dividual participant data of 74 565 participants from 23 co-
horts, subclinical thyroid dysfunction was not associated with
cognitive function, cognitive decline, or risk of dementia.
Hence, it is unlikely that treatment for otherwise undetected
subclinical thyroid dysfunction would improve cognitive func-
tion. Moreover, the chance of overtreatment is considerable,
which increases the risk of atrial fibrillation, atherosclerosis,
and cerebral infarction and thereby might increase the risk of
cognitive decline. Whether treatment of overt hypothyroid-
ism or hyperthyroidism is associated with cognitive decline and
risk of dementia remains uncertain. Existing clinical guide-
lines that prescribe screening of subclinical thyroid dysfunc-
tion for prevention of cognitive decline or dementia should
therefore be revisited.
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